Indoco Remedies Ltd
Q1 FY27, unaudited
- Revenue
- ₹408.97 Cr
- Profit after tax
- ₹82.32 Cr
As filed with the exchange, standalone basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 408.97 | +4.19% | 1,686.07 |
| Other income | 4.47 | −19.89% | 29.64 |
| Total income | 413.44 | +3.85% | 1,715.71 |
| Employee benefit expense | 90.65 | −7.97% | 393.63 |
| Finance costs | 22.75 | −3.64% | 88.50 |
| Depreciation & amortisation | 28.05 | +11.31% | 106.90 |
| Total expenses | 417.56 | −2.10% | 1,724.32 |
| Profit before tax | 93.22 | +428.24% | -11.47 |
| Tax expense | 10.90 | +3,305.88% | -5.81 |
| Profit after tax | 82.32 | +393.37% | -5.66 |
| Total comprehensive income | 81.87 | +396.09% | -4.33 |
| Earnings per share, basic | ₹8.92 | ₹-0.61 |
|---|---|---|
| Earnings per share, diluted | ₹8.92 | ₹-0.61 |
Earnings call
Q1 FY27Indoco Remedies reported standalone revenue growth of 5.8% year-on-year to Rs 4,081 million in Q1 FY27, with consolidated revenue up 8.2% to Rs 4,662 million. Standalone EBITDA margin expanded to 10.3% from 3.8% a year earlier, aided by cost efficiency measures including a reduction in headcount and fewer manufacturing batches. Management discussed regulatory approvals across its Baddi and Goa facilities, a pending USFDA audit for its sterile plant, and flat performance in European and emerging markets which it attributed to timing and one-off factors.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary
Earlier calls: Q4 FY26 · All quarters
Filings
12 shown · 36 published by the exchange
22 Aug 2026
Filing21 Aug 2026
21 Aug 2026
21 Aug 2026
FilingNotice Of 79Th Annual General Meeting And Annual Report For The Financial Year 2025-2026
Appears 2 times in the recent filings shown; listed once.
21 Aug 2026
20 Aug 2026
Filing04 Aug 2026
Transcript29 Jul 2026
Filing28 Jul 2026
28 Jul 2026
Filing28 Jul 2026
28 Jul 2026
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Page generated from filings held to 22 Aug 2026.